Could a Low-Dose arthritis drug ease a dangerous sickle cell complication?
NCT ID NCT05640271
First seen Jun 24, 2026 · Last updated Jul 15, 2026 · Updated 3 times
Summary
This phase 2 trial is testing whether a single low dose of tocilizumab, a drug that blocks inflammation, can help people with sickle cell disease who develop acute chest syndrome—a serious lung complication. Researchers will enroll 200 patients aged 12 and older and track their oxygen levels and need for blood transfusions. The goal is to see if this anti-inflammatory approach can improve recovery and reduce complications.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- tocilizumab (a drug that blocks interleukin-6, used for rheumatoid arthritis and COVID-19)
- What this could lead to
- If it works, this could provide a new, low-dose treatment for acute chest syndrome in sickle cell disease, potentially reducing the need for blood transfusions and improving oxygen levels.
- What could go wrong
- This is an early phase 2 trial with only 200 participants, so results may not apply to all patients. The drug may not improve outcomes and could cause side effects like infections or low blood cell counts.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE CHEST SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Chicago
RECRUITINGChicago, Illinois, 60637, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can Co-Designed support help parents embrace sickle cell care?
- Can community hospitals in zambia master severe disease care?
- A Pocket-Sized coach for sickle cell: can an app turn Pill-Taking into a habit?
- Can a phone app keep teens on track with sickle cell treatment?
- A common amino acid may calm sickle cell pain crises — a trial puts it to the test
- A drug that protects the liver may make stem cell transplants safer for children with sickle cell disease